Hapa, AslıAksoy, BernaPolat, MuallaAslan, UmutAtakan, Nilgün2021-06-232021-06-2320110954-6634https://doi.org/10.3109/09546631003675450https://hdl.handle.net/20.500.12491/6912Introduction: Quality of life measures are increasingly being used in the evaluation of oral disease outcome. To date, there has been less focus on oral health-related quality of life (OHR-QoL) measures for oral diseases in dermatologic literature. Objective: To test whether patients with recurrent aphthous stomatitis (RAS) report a lower OHR-QoL than the general population and to evaluate therapeutic regimens for RAS by using OHR-QoL measures. Method: A total of 128 patients and 40 controls were enrolled. A questionnaire entitled the 14-item oral health impact profile (OHIP-14) was completed. Forty-three (33%) of the patients were followed-up and completed the OHIP-14 following treatment. Results: The median total score of patients on colchicine before treatment was 21. Following use of colchicine, the total score was 10. There was a significant difference concerning the impact of oral health following use of oral colchicine. However, no reduction of OHIP-14 scores was observed in the topical treatment group. Conclusion: When the influence of one of the most common oral diseases such as RAS on OHR-QoL was taken into consideration, OHR-QoL provides an additional dimension that may help to improve the impact of a disease on an individual's life. In relation to this, colchicine seems to be one of the most effective management strategies used in RAS.eninfo:eu-repo/semantics/closedAccessOHIP-14Oral Mucosal DiseasesQuality of LifeRecurrent Aphthous StomatitisDoes recurrent aphthous stomatitis affect quality of life? A prospective study with 128 patients evaluating different treatment modalitiesArticle10.3109/09546631003675450224215220208044372-s2.0-79960444553Q1WOS:000292780600007Q3